.. Colonies-spontanées-mégacaryocytaires-versus-Érythrocytaires and .. La-polyglobulie-de-vaquez, 83 5.2.2.1, p.85

.. Et-perspectives, Discussion, Partie, vol.4, p.91

A. Tefferi and J. Vardiman, Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms, Leukemia, vol.5, issue.1, 2008.
DOI : 10.1038/sj.leu.2404955

J. Vizmanos, C. Ormazabal, M. Larrayoz, N. Cross, and M. Calasanz, JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients, Leukemia, vol.365, issue.3, 2006.
DOI : 10.1111/j.1365-2141.2005.05764.x

C. Smith and G. Fan, The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms, Human Pathology, vol.39, issue.6, pp.534-539, 2008.
DOI : 10.1016/j.humpath.2008.02.004

A. Moliterno, D. Williams, O. Rogers, and J. Spivak, Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression, Blood, vol.108, issue.12, pp.3913-3918, 2006.
DOI : 10.1182/blood-2006-03-008805

A. Jones, S. Kreil, K. Zoi, K. Waghorn, C. Curtis et al., Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders, Blood, vol.106, issue.6, pp.2162-2170, 2005.
DOI : 10.1182/blood-2005-03-1320

P. Johansson, Epidemiology of the Myeloproliferative Disorders Polycythemia Vera and Essential Thrombocythemia, Seminars in Thrombosis and Hemostasis, vol.32, issue.3, pp.171-174, 2006.
DOI : 10.1055/s-2006-939430

F. Girodon, G. Bonicelli, C. Schaeffer, M. Mounier, S. Carillo et al., Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study, Haematologica, vol.94, issue.6, pp.865-874, 2009.
DOI : 10.3324/haematol.2008.004234

X. Ma, G. Vanasse, B. Cartmel, Y. Wang, and H. Selinger, Prevalence of polycythemia vera and essential thrombocythemia, American Journal of Hematology, vol.139, issue.5, pp.359-62, 2008.
DOI : 10.1002/ajh.21129

M. Ruggeri, A. Tosetto, M. Frezzato, and F. Rodeghiero, The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis, 11. SFH. Polyglobulie primitive ou maladie de Vaquez. Hématologie, pp.470-5331, 2003.
DOI : 10.7326/0003-4819-139-6-200309160-00009

P. Johansson, J. Kutti, B. Andreasson, S. Safai-kutti, L. Vilen et al., Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99, Journal of Internal Medicine, vol.22, issue.1, pp.161-166, 2004.
DOI : 10.1034/j.1600-0609.2000.90236.x

R. Mcnally, R. D. Roman, E. Cartwright, R. Jd, and C. Billotey, Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol Epidemiological data in polycythaemia vera: a study of 842 cases, Hematol Cell Ther, vol.1540, issue.44, pp.173-89159, 1997.

N. Berlin, Diagnosis and classification of the polycythemias, Semin Hematol, 1975.

E. Jaffe, N. Harris, H. Stein, and J. Vardiman, World Health Organization of Tumors of Hematopoietic and Lymphoid tissues, 1920.

S. Aufaure, M. L. Oliver, and N. Baptiste, Thrombocytémie, carence martiale sans anémie : le concept d'une polyglobulie primitive masquée. La revue de gériatrie, pp.355-60, 1999.

N. Bénéton and P. Saiag, Stratégie diagnostique devant un prurit. Médecine thérapeutique, 2000.

G. Gerlini, F. Prignano, and N. Pimpinelli, Acute leucocytoclastic vasculitis and aquagenic pruritus long preceding polycythemia rubra vera, Eur J Dermatol, vol.12, issue.3, pp.270-271, 2002.

T. Lamy, A. Devillers, M. Bernard, A. Moisan, I. Grulois et al., Inapparent Polycythemia Vera: An Unrecognized Diagnosis, The American Journal of Medicine, vol.102, issue.1, pp.14-20, 1997.
DOI : 10.1016/S0002-9343(96)00351-8

D. Stefano, V. Fiorini, A. Rossi, E. Za, T. Farina et al., Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders, Journal of Thrombosis and Haemostasis, vol.18, issue.2, pp.708-722, 2007.
DOI : 10.1182/blood-2003-02-0443

M. Boissinot, E. Lippert, F. Girodon, I. Dobo, M. Fouassier et al., Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis, Blood, vol.108, issue.9, pp.3223-3227, 2006.
DOI : 10.1182/blood-2006-05-021527

F. Passamonti, E. Rumi, E. Pungolino, L. Malabarba, P. Bertazzoni et al., Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders, Am J Med Leukemia, vol.11722, issue.275, pp.755-61905, 2004.

E. Lengfelder, A. Hochhaus, U. Kronawitter, D. Hoche, W. Queisser et al., /l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Br J Haematol. Blood. Jul, vol.600100114, issue.305, pp.15-23937, 1998.

R. Mesa, J. Niblack, M. Wadleigh, S. Verstovsek, J. Camoriano et al., The burden of fatigue and quality of life in myeloproliferative disorders (MPDs), Cancer, vol.33, issue.1, pp.68-76, 2007.
DOI : 10.1002/cncr.22365

M. Jensen, P. De-nully-brown, O. Nielsen, and H. Hasselbalch, Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area, European Journal of Haematology, vol.65, issue.2, 2000.
DOI : 10.1034/j.1600-0609.2000.90236.x

L. Teofili, R. Foa, F. Giona, and L. Larocca, Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?, Haematologica, vol.93, issue.2, 2008.
DOI : 10.3324/haematol.12002

R. Mesa, S. Verstovsek, F. Cervantes, G. Barosi, J. Reilly et al., Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT), Leukemia Research, vol.31, issue.6, 2007.
DOI : 10.1016/j.leukres.2006.12.002

M. Maynadie, F. Girodon, I. Manivet-janoray, M. Mounier, F. Mugneret et al., Twentyfive years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France) Haematologica Woodliff HJ, Dougan L. Myelofibrosis in Western Australia: an epidemiological study of 29 cases Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, Med J Aust Apr, vol.961112, issue.361, pp.55-61523, 1976.

R. Mesa, M. Silverstein, S. Jacobsen, P. Wollan, and A. Tefferi, Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995, Am J Hematol. Ridell B, Carneskog J Eur J Haematol, vol.61, issue.38, pp.10-15, 1983.

S. Ciurea, D. Merchant, N. Mahmud, T. Ishii, Y. Zhao et al., Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis, Blood, vol.110, issue.3, pp.267-71986, 2007.
DOI : 10.1182/blood-2006-12-064626

A. Tefferi, Pathogenesis of Myelofibrosis With Myeloid Metaplasia, Journal of Clinical Oncology, vol.23, issue.33, pp.8520-8550, 2005.
DOI : 10.1200/JCO.2004.00.9316

R. Jacobson, A. Salo, and P. Fialkow, Agnogenic Myeloid Metaplasia, Radiology, vol.72, issue.5, pp.189-94, 1978.
DOI : 10.1148/72.5.716

L. Bousse-kerdiles, M. Praloran, V. Martyre, M. Florena, A. Tripodo et al., La splénomégalie myéloïde : De données récentes à un modèle physiopathologique. Hématologie Value of bone marrow biopsy in the diagnosis of essential thrombocythemia, Haematologica, vol.889, issue.438, pp.187-96911, 2002.

U. Gianelli, C. Vener, P. Raviele, A. Moro, F. Savi et al., Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes, Blood, vol.47111, issue.451, pp.1774-8160, 2006.

M. Brousseau, E. Parot-schinkel, M. Moles, F. Boyer, M. Hunault et al., Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis, Histopathology, vol.88, issue.6, pp.758-67, 2010.
DOI : 10.1111/j.1365-2559.2010.03545.x

J. Thiele, H. Kvasnicka, L. Mullauer, V. Buxhofer-ausch, B. Gisslinger et al., Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification, Blood, vol.117, issue.21, pp.5710-5718, 2011.
DOI : 10.1182/blood-2010-07-293761

T. Barbui, J. Thiele, F. Passamonti, E. Rumi, E. Boveri et al., Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study, Journal of Clinical Oncology, vol.29, issue.23, pp.3179-84, 2011.
DOI : 10.1200/JCO.2010.34.5298

R. Landolfi, D. Gennaro, L. Falanga, and A. , Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation, Leukemia, vol.38, issue.11, pp.2020-2028, 2008.
DOI : 10.1038/leu.2008.253

R. Marchioli, G. Finazzi, R. Landolfi, J. Kutti, H. Gisslinger et al., Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera, Journal of Clinical Oncology, vol.23, issue.10, pp.2224-2256, 2005.
DOI : 10.1200/JCO.2005.07.062

S. Cortelazzo, P. Viero, G. Finazzi, D. Emilio, A. Rodeghiero et al., Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia., Journal of Clinical Oncology, vol.8, issue.3, pp.556-62, 1990.
DOI : 10.1200/JCO.1990.8.3.556

M. Elliott, A. Pardanani, T. Lasho, S. Schwager, and A. Tefferi, Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked, Haematologica, vol.95, issue.10, 2010.
DOI : 10.3324/haematol.2010.025064

J. Kiladjian, F. Cervantes, F. Leebeek, C. Marzac, B. Cassinat et al., The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases, Blood, vol.111, issue.10, pp.1788-91, 2008.
DOI : 10.1182/blood-2007-11-125328

M. Primignani, G. Barosi, G. Bergamaschi, U. Gianelli, F. Fabris et al., Role of theJAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis, Hepatology, vol.51, issue.6, pp.1528-1562, 2006.
DOI : 10.1002/hep.21435

C. Goulding, B. Uttenthal, L. Foroni, V. Duke, A. Traore et al., tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis, International Journal of Laboratory Hematology, vol.280, issue.5, pp.415-424, 2008.
DOI : 10.1111/j.1751-553X.2007.00973.x

C. Harrison, Platelets and Thrombosis in Myeloproliferative Diseases, Hematology, vol.2005, issue.1, pp.409-424, 2005.
DOI : 10.1182/asheducation-2005.1.409

T. Pearson and G. Wetherley-mein, Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia, Lancet, vol.2, issue.8102, pp.1219-1241, 1978.

R. Landolfi, D. Gennaro, L. Barbui, T. , D. Stefano et al., Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood Leukocytosis and risk stratification assessment in essential thrombocythemia Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, J Clin Oncol Jun, vol.10926110, issue.623, pp.2446-522732, 2007.

M. Elliott, A. Tefferi, J. Michiels, Z. Berneman, W. Schroyens et al., Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost, Br J Haematol. Feb, vol.12832, issue.646, pp.275-90589, 2005.

A. Vannucchi, Diagnosis and treatment of polycythemia vera and essential thrombocythemia, Hematol J, vol.5, issue.1, pp.255-63, 2011.

C. Tam, H. Kantarjian, J. Cortes, A. Lynn, S. Pierce et al., Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post???Polycythemia Vera/Essential Thrombocythemia Myelofibrosis, Journal of Clinical Oncology, vol.27, issue.33, pp.5587-93, 2009.
DOI : 10.1200/JCO.2009.22.8833

R. Mesa, Assessing New Therapies and Their Overall Impact in Myelofibrosis, Hematology, vol.2010, issue.1, pp.115-136
DOI : 10.1182/asheducation-2010.1.115

F. Passamonti, E. Rumi, L. Arcaini, E. Boveri, C. Elena et al., Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients, Haematologica, vol.93, issue.11, pp.1645-51, 2008.
DOI : 10.3324/haematol.13346

A. Wolanskyj, S. Schwager, R. Mcclure, D. Larson, and A. Tefferi, Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors, Mayo Clinic Proceedings, vol.81, issue.2, pp.159-66, 2006.
DOI : 10.4065/81.2.159

F. Cervantes, A. Alvarez-larran, C. Talarn, M. Gomez, E. Montserrat et al., Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients, British Journal of Haematology, vol.83, issue.3, pp.786-90, 2002.
DOI : 10.1046/j.1365-2141.2002.03688.x

G. Sébahoun, Hématologie clinique et biologique, 2005.

T. Barbui, G. Barosi, G. Birgegard, F. Cervantes, G. Finazzi et al., Philadelphianegative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet, J Clin Oncol Feb, vol.2029, issue.6, pp.761-70, 2011.

F. Passamonti, E. Rumi, L. Arcaini, C. Elena, C. Castagnola et al., Blast phase of essential thrombocythemia: A single center study, American Journal of Hematology, vol.107, issue.10, pp.641-645, 2009.
DOI : 10.1002/ajh.21496

F. Passamonti, E. Rumi, C. Elena, L. Arcaini, M. Merli et al., Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence, Br J Haematol, 2010.

G. Finazzi, V. Caruso, R. Marchioli, G. Capnist, T. Chisesi et al., Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study, Blood, vol.105, issue.7, pp.2664-70, 2005.
DOI : 10.1182/blood-2004-09-3426

M. Randi, F. Fabris, and A. Girolami, Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia, Leuk Lymphoma, vol.37, pp.3-4379, 2000.

G. Finazzi, M. Ruggeri, F. Rodeghiero, T. Barbui, Y. Sterkers et al., Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan, P. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes, pp.3749-79616, 1998.

G. Finazzi, T. Barbui, . Pa, F. Delhommeau, J. Lecouedic et al., How I treat patients with polycythemia vera, Blood, vol.109, issue.12, pp.5104-5115, 2007.
DOI : 10.1182/blood-2006-12-038968

K. Hussein, D. Van-dyke, and A. Tefferi, Conventional cytogenetics in myelofibrosis: literature review and discussion, European Journal of Haematology, vol.110, issue.5, pp.329-367, 2009.
DOI : 10.1111/j.1600-0609.2009.01224.x

N. Gangat, J. Strand, T. Lasho, C. Finke, R. Knudson et al., Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates Myeloproliferative disorders, Eur J Haematol. Bench AJ Best Pract Res Clin Haematol, vol.8014, issue.863, pp.197-200531, 2001.

N. Gangat, A. Tefferi, G. Thanarajasingam, M. Patnaik, S. Schwager et al., Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance, European Journal of Haematology, vol.255, issue.1, pp.17-21, 2009.
DOI : 10.1111/j.1600-0609.2009.01246.x

J. Reilly, Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). Leukemia, 2008.

A. Tefferi, R. Skoda, and J. Vardiman, Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics, Nature Reviews Clinical Oncology, vol.133, issue.11, pp.1818-27627, 2009.
DOI : 10.1038/nrclinonc.2009.149

F. Passamonti, M. Maffioli, D. Caramazza, and M. Cazzola, Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies, Oncotarget, vol.2, issue.6, pp.485-90, 2011.
DOI : 10.18632/oncotarget.281

C. Ricci, O. Spinelli, S. Salmoiraghi, G. Finazzi, A. Carobbio et al., ASXL1 mutations in primary and secondary myelofibrosisAvailable on line. 92 A gain-of-function mutation of JAK2 in myeloproliferative disorders, Br J Haematol N Engl J Med, vol.352, issue.17, pp.1779-90, 2005.

R. Levine, M. Wadleigh, J. Cools, B. Ebert, G. Wernig et al., Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, pp.387-97, 2005.

C. James, V. Ugo, L. Couedic, J. Staerk, J. Delhommeau et al., A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol.100, issue.7037, pp.1144-1152, 2005.
DOI : 10.1182/blood-2002-09-2839

E. Baxter, L. Scott, P. Campbell, C. East, N. Fourouclas et al., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, pp.1054-61, 2005.

J. Staerk, A. Kallin, Y. Royer, C. Diaconu, A. Dusa et al., JAK2, the??JAK2 V617F mutant and??cytokine receptors, Pathologie Biologie, vol.55, issue.2, pp.88-91, 2007.
DOI : 10.1016/j.patbio.2006.06.003

J. Ihle and D. Gilliland, Jak2: normal function and role in hematopoietic disorders, Current Opinion in Genetics & Development, vol.17, issue.1, pp.8-14, 2007.
DOI : 10.1016/j.gde.2006.12.009

L. Scott, M. Scott, P. Campbell, and A. Green, Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia, Blood, vol.108, issue.7, pp.2435-2442, 2006.
DOI : 10.1182/blood-2006-04-018259

S. Dupont, A. Masse, C. James, I. Teyssandier, Y. Lecluse et al., The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera, Blood, vol.110, issue.3, pp.1013-1034, 2007.
DOI : 10.1182/blood-2006-10-054940

P. Campbell and A. Green, The Myeloproliferative Disorders, New England Journal of Medicine, vol.355, issue.23, pp.2452-66, 2006.
DOI : 10.1056/NEJMra063728

H. Lodish, A. Berk, P. Matsudaira, and C. Kaiser, Biologie moléculaire de la cellule, 2005.

A. Tefferi, S. Sirhan, T. Lasho, S. Schwager, C. Li et al., Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia, British Journal of Haematology, vol.95, issue.2, pp.166-71, 2005.
DOI : 10.1074/jbc.C500138200

S. Verstovsek, R. Silver, N. Cross, and A. Tefferi, JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?, Leukemia, vol.20, issue.11, p.2067, 2006.
DOI : 10.1182/blood-2005-03-1320

A. J. Tefferi, T. Mpl, A. , C. Idh, and I. Leukemia, Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms, pp.1128-1166, 2010.

C. Cleyrat, J. Jelinek, F. Girodon, M. Boissinot, T. Ponge et al., JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5, Leukemia, vol.24, issue.5, 2010.
DOI : 10.3324/haematol.13081

F. Grunebach, U. Bross-bach, L. Kanz, and P. Brossart, Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera, Leukemia, vol.19, issue.12, pp.2210-2211, 2006.
DOI : 10.1038/sj.leu.2404419

P. Sidon, E. Housni, H. Dessars, B. Heimann, and P. , The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors, Leukemia, vol.256, issue.9, p.1622, 2006.
DOI : 10.1038/sj.leu.2404292

C. Nielsen, H. Birgens, B. Nordestgaard, L. Kjaer, and S. Bojesen, The JAK2 V617F somatic mutation, mortality and cancer risk in the general population, Haematologica, vol.96, issue.3, pp.450-453, 2011.
DOI : 10.3324/haematol.2010.033191

X. Xu, Q. Zhang, J. Luo, S. Xing, Q. Li et al., JAK2V617F: prevalence in a large Chinese hospital population, Blood, vol.109, issue.1, pp.339-381, 2007.
DOI : 10.1182/blood-2006-03-009472

C. Martinaud, P. Brisou, and M. Mozziconacci, mutation detectable in healthy volunteers?, American Journal of Hematology, vol.94, issue.4, pp.287-295, 2010.
DOI : 10.1002/ajh.21627

R. Levine, M. Loriaux, B. Huntly, M. Loh, M. Beran et al., The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia, Blood, vol.106, issue.10, pp.3377-3386, 2005.
DOI : 10.1182/blood-2005-05-1898

S. Frohling, D. Lipka, S. Kayser, C. Scholl, R. Schlenk et al., Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7, Blood, vol.107, issue.3, pp.1242-1245, 2006.
DOI : 10.1182/blood-2005-09-3644

D. Steensma, G. Dewald, T. Lasho, H. Powell, R. Mcclure et al., The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes, Blood, vol.106, issue.4, pp.1207-1216, 2005.
DOI : 10.1182/blood-2005-03-1183

H. Szpurka, R. Tiu, G. Murugesan, S. Aboudola, E. Hsi et al., Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation, Blood, vol.108, issue.7, pp.2173-81, 2006.
DOI : 10.1182/blood-2006-02-005751

K. Lim, A. Tefferi, T. Lasho, C. Finke, M. Patnaik et al., Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors, Blood, vol.113, issue.23, pp.5727-5763, 2009.
DOI : 10.1182/blood-2009-02-205237

E. Hellstrom-lindberg and M. Cazzola, The Role of JAK2 Mutations in RARS and Other MDS, Hematology, vol.2008, issue.1, pp.52-61, 2008.
DOI : 10.1182/asheducation-2008.1.52

A. Remacha, J. Nomdedeu, G. Puget, C. Estivill, M. Sarda et al., Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis, Haematologica, vol.91, issue.5, pp.719-739, 2006.

M. Ceesay, N. Lea, W. Ingram, N. Westwood, J. Gaken et al., The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia, pp.2060-2061, 2006.

A. Schmitt-graeff, S. Teo, M. Olschewski, F. Schaub, S. Haxelmans et al., JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis, Haematologica, vol.93, issue.1, pp.34-40, 2008.
DOI : 10.3324/haematol.11581

L. Scott, W. Tong, R. Levine, M. Scott, P. Beer et al., JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis, N Engl J Med Feb, vol.1356, issue.5, pp.459-68, 2007.

F. Passamonti, E. Rumi, D. Pietra, C. Elena, E. Boveri et al., A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications, Leukemia, vol.22, issue.9, 2010.
DOI : 10.1038/leu.2010.148

M. Percy, P. Beer, G. Campbell, A. Dekker, A. Green et al., Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis, Blood, vol.111, issue.11, pp.5400-5402, 2008.
DOI : 10.1182/blood-2008-02-137703

L. Scott, The JAK2 exon 12 mutations: A comprehensive review, American Journal of Hematology, vol.106, issue.8, 2011.
DOI : 10.1002/ajh.22063

C. Ormazabal, C. Hurtado, P. Aranaz, I. Erquiaga, M. Garcia-delgado et al., Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs, Leukemia Research, vol.32, issue.9, pp.1485-1492, 2008.
DOI : 10.1016/j.leukres.2008.01.002

C. Butcher, U. Hahn, L. To, J. Gecz, E. Wilkins et al., Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients, Leukemia, vol.365, issue.4, pp.870-873, 2008.
DOI : 10.1111/j.1365-2141.2007.06497.x

A. Pardanani, T. Lasho, C. Finke, C. Hanson, and A. Tefferi, Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia, 2007.

S. Li, R. Kralovics, D. Libero, G. Theocharides, A. Gisslinger et al., Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations, Blood, vol.111, issue.7, pp.3863-3869, 2008.
DOI : 10.1182/blood-2007-09-111971

M. Lakey, A. Pardanani, J. Hoyer, P. Nguyen, T. Lasho et al., Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations, Am J Clin Pathol, 2010.

F. Passamonti, C. Elena, S. Schnittger, R. Skoda, A. Green et al., Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood, pp.2813-2819, 2011.

V. Ugo, S. Tondeur, M. Menot, N. Bonnin, L. Gac et al., Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients, PLoS ONE, vol.5, issue.1, p.8893, 2010.
DOI : 10.1371/journal.pone.0008893.t001

A. Moliterno, D. Williams, L. Gutierrez-alamillo, R. Salvatori, R. Ingersoll et al., Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis, Proceedings of the National Academy of Sciences, vol.101, issue.31, pp.11444-11451, 2004.
DOI : 10.1073/pnas.0404241101

Y. Pikman, B. Lee, T. Mercher, E. Mcdowell, B. Ebert et al., MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia, PLoS Medicine, vol.102, issue.7, p.270, 2006.
DOI : 10.1371/journal.pmed.0030270.st001

E. Boyd, A. Bench, A. Goday-fernandez, S. Anand, K. Vaghela et al., exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis, British Journal of Haematology, vol.35, issue.2, pp.250-257, 2010.
DOI : 10.1111/j.1365-2141.2010.08083.x

J. Staerk, C. Lacout, T. Sato, S. Smith, W. Vainchenker et al., An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor, Blood, vol.107, issue.5, pp.1864-71, 2006.
DOI : 10.1182/blood-2005-06-2600

A. Pardanani, P. Guglielmelli, T. Lasho, A. Pancrazzi, C. Finke et al., Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients, Leukemia, vol.25, issue.12, 2011.
DOI : 10.1182/blood-2009-04-216044

G. Ruan, B. Jiang, L. Li, J. Niu, J. Li et al., W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes, Hematological Oncology, vol.110, issue.5, pp.33-42, 2010.
DOI : 10.1002/hon.899

A. Pardanani, R. Levine, T. Lasho, Y. Pikman, R. Mesa et al., MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, Blood, vol.108, issue.10, pp.3472-3478, 2006.
DOI : 10.1182/blood-2006-04-018879

P. Beer, P. Campbell, L. Scott, A. Bench, W. Erber et al., MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort, Blood, vol.112, issue.1, pp.141-150, 2008.
DOI : 10.1182/blood-2008-01-131664

S. Oh, E. Simonds, C. Jones, M. Hale, Y. Goltsev et al., Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms, Blood, vol.116, issue.6, pp.988-92, 2010.
DOI : 10.1182/blood-2010-02-270108

S. Gery, Q. Cao, S. Gueller, H. Xing, A. Tefferi et al., Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F, Journal of Leukocyte Biology, vol.85, issue.6, pp.957-65, 2009.
DOI : 10.1189/jlb.0908575

T. Lasho, A. Pardanani, and A. Tefferi, Mutation???Negative Erythrocytosis, New England Journal of Medicine, vol.363, issue.12, pp.1189-90, 2010.
DOI : 10.1056/NEJMc1006966

J. Ha and D. Jeon, Possible new LNK mutations in myeloproliferative neoplasms, American Journal of Hematology, vol.86, issue.10, pp.866-874, 2011.
DOI : 10.1002/ajh.22107

A. Pardanani, T. Lasho, C. Finke, S. Oh, J. Gotlib et al., LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations, Leukemia, vol.118, issue.10, pp.1713-1721, 2010.
DOI : 10.1158/0008-5472.CAN-09-3783

J. Guo, Y. Su, C. Zhong, G. Ming, and H. Song, Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell, pp.423-457, 2011.

J. Guo, Y. Su, C. Zhong, G. Ming, and H. Song, Emerging roles of TET proteins and 5- hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle, Aug, vol.1510, issue.16, pp.2662-2670, 2011.

O. Abdel-wahab, Genetics of the myeloproliferative neoplasms, Curr Opin Hematol, 2011.

A. Tefferi, A. Pardanani, K. Lim, O. Abdel-wahab, T. Lasho et al., TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis, Leukemia, vol.22, issue.5, pp.905-916, 2009.
DOI : 10.1038/leu.2009.47

F. Delhommeau, S. Dupont, D. Valle, V. James, C. Trannoy et al., in Myeloid Cancers, New England Journal of Medicine, vol.360, issue.22, pp.2289-301, 2009.
DOI : 10.1056/NEJMoa0810069

A. Tefferi, K. Lim, O. Abdel-wahab, T. Lasho, J. Patel et al., Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms, pp.1343-1348, 2009.

S. Langemeijer, J. Jansen, J. Hooijer, P. Van-hoogen, E. Stevens-linders et al., TET2 mutations in childhood leukemia, Leukemia, vol.25, issue.1, pp.189-92, 2011.
DOI : 10.1038/nature09303

A. Tefferi, R. Levine, K. Lim, O. Abdel-wahab, T. Lasho et al., Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates, Leukemia, vol.16, issue.5, 2009.
DOI : 10.1038/leu.2009.37

O. Abdel-wahab, T. Manshouri, J. Patel, K. Harris, J. Yao et al., Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res, pp.447-52, 2010.

T. Ernst, A. Chase, J. Score, C. Hidalgo-curtis, C. Bryant et al., Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders, Nature Genetics, vol.8, issue.8, pp.722-728, 2010.
DOI : 10.1016/j.molcel.2008.10.016

O. Abdel-wahab, A. Pardanani, J. Patel, M. Wadleigh, T. Lasho et al., Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms, Leukemia, vol.25, issue.7, pp.1200-1202, 2010.
DOI : 10.1182/blood-2010-06-293415

W. Vainchenker, F. Delhommeau, S. Constantinescu, and O. Bernard, New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 2011.

P. Beer, W. Erber, P. Campbell, and A. Green, How I treat essential thrombocythemia. Blood, Feb, vol.3117, issue.5, pp.1472-82, 2011.

A. Vannucchi, Diagnosis and treatment of polycythemia vera and essential thrombocythemia. Hematology Education: Annual congress of the European Hematology Association, pp.255-63, 2011.

A. Tefferi, Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series: Polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management, American Journal of Hematology, vol.110, issue.3, pp.292-301, 2011.
DOI : 10.1002/ajh.21946

R. Landolfi, R. Marchioli, J. Kutti, H. Gisslinger, G. Tognoni et al., Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera, New England Journal of Medicine, vol.350, issue.2, pp.114-138, 2004.
DOI : 10.1056/NEJMoa035572

A. Alvarez-larran, F. Cervantes, A. Pereira, E. Arellano-rodrigo, V. Perez-andreu et al., Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood, pp.1205-1215, 2010.

D. Nisio, M. Barbui, T. , D. Gennaro, L. Borrelli et al., The haematocrit and platelet target in polycythemia vera, British Journal of Haematology, vol.128, issue.2, pp.249-59, 2007.
DOI : 10.1007/BF01707281

J. Spivak, Polycythemia vera: myths, mechanisms, and management, Blood, vol.100, issue.13, pp.4272-90, 2002.
DOI : 10.1182/blood-2001-12-0349

I. Tatarsky and R. Sharon, Management of polycythemia vera with hydroxyurea, Semin Hematol, vol.34, issue.1, pp.24-32, 1997.

W. West, Hydroxyurea in the Treatment of Polycythemia Vera: A Prospective Study of 100 Patients Over a 20-Year Period, Southern Medical Journal, vol.80, issue.3, pp.323-330, 1987.
DOI : 10.1097/00007611-198703000-00012

J. Kiladjian, S. Chevret, C. Dosquet, C. Chomienne, and J. Rain, Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980, Journal of Clinical Oncology, vol.29, issue.29, pp.3907-3920, 2011.
DOI : 10.1200/JCO.2011.36.0792

J. Spivak, An inconvenient truth. Blood, pp.2727-2735, 2010.

M. Martyre, Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia, Curr Hematol Rep, vol.2, issue.3, pp.257-63, 2003.

A. Quintas-cardama, H. Kantarjian, T. Manshouri, R. Luthra, Z. Estrov et al., Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera, Journal of Clinical Oncology, vol.27, issue.32, pp.5418-5442, 2009.
DOI : 10.1200/JCO.2009.23.6075

J. Kiladjian, B. Cassinat, S. Chevret, P. Turlure, N. Cambier et al., Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera, Blood, vol.112, issue.8, pp.3065-72, 2008.
DOI : 10.1182/blood-2008-03-143537

G. Barosi, G. Birgegard, G. Finazzi, M. Griesshammer, C. Harrison et al., A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process, British Journal of Haematology, vol.22, issue.6, pp.961-964, 2010.
DOI : 10.1111/j.1365-2141.2009.08019.x

G. Barosi, G. Birgegard, G. Finazzi, M. Griesshammer, C. Harrison et al., Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference, Blood, vol.113, issue.20, pp.4829-4862, 2009.
DOI : 10.1182/blood-2008-09-176818

L. Solberg, J. Tefferi, A. Oles, K. Tarach, J. Petitt et al., The effects of anagrelide on human megakaryocytopoiesis, British Journal of Haematology, vol.99, issue.1, pp.174-80, 1997.
DOI : 10.1046/j.1365-2141.1997.3503164.x

C. Harrison, P. Campbell, G. Buck, K. Wheatley, C. East et al., Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia, New England Journal of Medicine, vol.353, issue.1, pp.33-45, 2005.
DOI : 10.1056/NEJMoa043800

J. Michiels, P. Van-genderen, J. Lindemans, and H. Van-vliet, Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leuk Lymphoma, pp.47-56, 1996.

F. Diehn and A. Tefferi, Pruritus in polycythaemia vera: prevalence, laboratory correlates and management, British Journal of Haematology, vol.96, issue.3, pp.619-640, 2001.
DOI : 10.1016/S0140-6736(88)92254-4

A. Tefferi and R. Fonseca, Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood, p.2627, 2002.

A. Baldo, E. Sammarco, R. Plaitano, V. Martinelli, . Monfrecola et al., Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera, British Journal of Dermatology, vol.71, issue.5, pp.979-81, 2002.
DOI : 10.1046/j.1365-2133.1998.02403.x

E. Lengfelder, U. Berger, and R. Hehlmann, Interferon alpha in the treatment of polycythemia vera

A. Pardanani and A. Tefferi, Targeting myeloproliferative neoplasms with JAK inhibitors, Current Opinion in Hematology, vol.18, issue.2, pp.105-115, 2011.
DOI : 10.1097/MOH.0b013e3283439964

F. Guilhot, Les syndromes myéloprolifératifs, 2008.

C. Harrison, Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera, Hematology, vol.2010, issue.1, pp.129-163
DOI : 10.1182/asheducation-2010.1.129

D. Caramazza, K. Begna, N. Gangat, R. Vaidya, S. Siragusa et al., Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients, Leukemia, vol.25, issue.1, pp.82-90, 2011.
DOI : 10.1111/j.1365-2141.2007.06776.x

N. Gangat, D. Caramazza, R. Vaidya, G. George, K. Begna et al., DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status, Journal of Clinical Oncology, vol.29, issue.4, pp.392-399, 2011.
DOI : 10.1200/JCO.2010.32.2446

F. Cervantes, B. Dupriez, A. Pereira, F. Passamonti, J. Reilly et al., New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment, Blood, vol.113, issue.13, pp.2895-901, 2009.
DOI : 10.1182/blood-2008-07-170449

A. Tefferi, T. Jimma, N. Gangat, R. Vaidya, K. Begna et al., Predictors of greater than 80% two-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically-annotated patients. Blood, 2011.

A. Tefferi, R. Vaidya, D. Caramazza, C. Finke, T. Lasho et al., Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study, Journal of Clinical Oncology, vol.29, issue.10, pp.1356-63, 2011.
DOI : 10.1200/JCO.2010.32.9490

A. Tefferi, T. Lasho, R. Mesa, A. Pardanani, R. Ketterling et al., Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions, Leukemia, vol.30, issue.8, pp.1827-1835, 2007.
DOI : 10.1038/sj.leu.2404711

R. Santana-davila, A. Tefferi, S. Holtan, R. Ketterling, G. Dewald et al., Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): Clinicopathologic comparison of del(5q)-positive and -negative cases, Leukemia Research, vol.32, issue.12, 2008.
DOI : 10.1016/j.leukres.2008.04.022

A. Tefferi, How I treat myelofibrosis. Blood, pp.3494-504, 2011.

F. Cervantes, A. Alvarez-larran, J. Hernandez-boluda, A. Sureda, M. Torrebadell et al., Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature, British Journal of Haematology, vol.86, issue.4, pp.399-403, 2004.
DOI : 10.1016/S0268-960X(97)90022-9

J. Huang and A. Tefferi, Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level, European Journal of Haematology, vol.82, issue.2
DOI : 10.1111/j.1600-0609.2009.01266.x

R. Weinkove, J. Reilly, M. Mcmullin, N. Curtin, D. Radia et al., Low-dose thalidomide in myelofibrosis, Haematologica, vol.93, issue.7, pp.1100-1101, 2008.
DOI : 10.3324/haematol.12416

F. Durupt, J. Coutet, B. Salles, J. Penaud, and S. Durupt, Thalidomide en 2005 : mise au point et utilisation pratique Journal de pharmacie clinique. 2005 juillet-août-septembre, pp.145-57

M. Steurer, I. Sudmeier, R. Stauder, and G. Gastl, Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha, British Journal of Haematology, vol.95, issue.1, pp.101-104, 2003.
DOI : 10.1182/blood-2002-01-0335

R. Mesa, X. Yao, L. Cripe, C. Li, M. Litzow et al., Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood Site internet, pp.4436-4444, 0197.

R. Mesa, How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood, 2009.

G. Barugola, A. Cavallini, G. Lipari, G. Armatura, W. Mantovani et al., The role of splenectomy in myelofibrosis with myeloid metaplasia. Minerva Chir, pp.619-644, 2010.

R. Mesa, D. Nagorney, S. Schwager, J. Allred, and A. Tefferi, Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosiswith myeloid metaplasia at the Mayo Clinic, Cancer, vol.91, issue.2, pp.361-70, 2006.
DOI : 10.1002/cncr.22021

M. Robin, R. Tabrizi, M. Mohty, S. Furst, M. Michallet et al., Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Soci??t?? Fran??aise de Greffe de Moelle et de Th??rapie Cellulaire (SFGM-TC), British Journal of Haematology, vol.27, issue.3, pp.331-340, 2011.
DOI : 10.1111/j.1365-2141.2010.08417.x

K. Ballen, S. Shrestha, K. Sobocinski, M. Zhang, A. Bashey et al., Outcome of Transplantation for Myelofibrosis, Biology of Blood and Marrow Transplantation, vol.16, issue.3, pp.358-67, 2010.
DOI : 10.1016/j.bbmt.2009.10.025

A. Bacigalupo, M. Soraru, A. Dominietto, S. Pozzi, S. Geroldi et al., Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type, Bone Marrow Transplantation, vol.28, issue.3, pp.458-63, 2010.
DOI : 10.1097/01.moh.0000203191.99447.98

F. Patriarca, A. Bacigalupo, A. Sperotto, M. Isola, F. Soldano et al., Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Haematologica, vol.93, issue.10, pp.1514-1536, 2008.
DOI : 10.3324/haematol.12828

N. Kroger, A. Badbaran, E. Holler, J. Hahn, G. Kobbe et al., Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood, Feb, vol.1109, issue.3, pp.1316-1337, 2007.

K. Begna, R. Mesa, A. Pardanani, W. Hogan, M. Litzow et al., A phase-2 trial of low-dose pomalidomide in myelofibrosis, Leukemia, vol.85, issue.2, pp.301-305, 2011.
DOI : 10.1182/blood-2009-08-240135

S. Verstovsek, H. Kantarjian, R. Mesa, A. Pardanani, J. Cortes-franco et al., Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis, New England Journal of Medicine, vol.363, issue.12, pp.1117-1144, 2010.
DOI : 10.1056/NEJMoa1002028

A. Pardanani, A. Vannucchi, F. Passamonti, F. Cervantes, T. Barbui et al., JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations, Leukemia, vol.112, issue.2, pp.218-243, 2011.
DOI : 10.1016/j.ccr.2009.10.015

A. Deshpande, M. Reddy, G. Schade, A. Ray, T. Chowdary et al., Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms, Leukemia, vol.63, issue.4, 2011.
DOI : 10.1172/JCI42442

M. Bornhauser, B. Mohr, U. Oelschlaegel, P. Bornhauser, J. S. Ehninger et al., Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis, Leukemia, vol.20, issue.8, pp.1824-1830, 2007.
DOI : 10.1038/sj.leu.2404730

K. Hussein, O. Bock, A. Seegers, M. Flasshove, F. Henneke et al., Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation, Blood, vol.109, issue.9, pp.4106-4113, 2007.
DOI : 10.1182/blood-2006-12-061135

G. Busche, K. Hussein, O. Bock, and H. Kreipe, Insights into JAK2-V617F mutation in CML, The Lancet Oncology, vol.8, issue.10, pp.863-867, 2007.
DOI : 10.1016/S1470-2045(07)70294-2

M. Inami, H. Yamaguchi, S. Hasegawa, Y. Mitamura, F. Kosaka et al., Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia, Leukemia, vol.13, issue.1, p.216, 2008.
DOI : 10.1038/sj.leu.2404953

M. Lanotte, Terminal differentiation of hemopoietic cell clones cultured in tridimensional collagen matrix: in situ cell morphology and enzyme histochemistry analysis, Biology of the Cell, vol.50, issue.2, pp.107-127, 1984.
DOI : 10.1111/j.1768-322X.1984.tb00257.x

R. Berthier, O. Valiron, A. Schweitzer, and G. Marguerie, Serum‐free medium allows the optimal growth of human megakaryocyte progenitors compared with human plasma supplemented cultures: Role of TGF β, Stem Cells, vol.77, issue.2, pp.120-129, 1993.
DOI : 10.1002/stem.5530110207

I. Dobo, M. Donnard, F. Girodon, P. Mossuz, N. Boiret et al., Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera, The Hematology Journal, vol.5, issue.2, pp.161-168, 2004.
DOI : 10.1038/sj.thj.6200344

I. Dobo, N. Boiret, E. Lippert, F. Girodon, P. Mossuz et al., A standardized endogenous megakaryocytic erythroid colony assay for the diagnosis of essential thrombocythemia, Haematologica, vol.89, issue.10, pp.1207-1219, 2004.

M. Vemuri, Stem Cell Assays, 2008.
DOI : 10.1007/978-1-59745-536-7

C. Nissen-druey, A. Tichelli, and S. Meyer-monard, Human hematopoietic colonies in health and disease, Acta Haematol, vol.113, issue.1, pp.5-96, 2005.
DOI : 10.1159/isbn.978-3-318-01187-6

Q. Chen, P. Lu, A. Jones, N. Cross, R. Silver et al., Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders, The Journal of Molecular Diagnostics, vol.9, issue.2, pp.272-278, 2007.
DOI : 10.2353/jmoldx.2007.060133

A. Tefferi, L. Solberg, and M. Silverstein, A clinical update in polycythemia vera and essential thrombocythemia, The American Journal of Medicine, vol.109, issue.2, pp.141-150, 2000.
DOI : 10.1016/S0002-9343(00)00449-6

C. Reid, The significance of endogenous erythroid colonies (EEC) in haematological disorders, Blood Reviews, vol.1, issue.2, pp.133-173, 1987.
DOI : 10.1016/0268-960X(87)90008-7

L. Sokol, G. Caceres, K. Rocha, K. Stockero, D. Dewald et al., JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones, Leuk Res, 2010.

D. Veneri, E. Capuzzo, G. De-matteis, M. Franchini, E. Baritono et al., Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques, Blood Transfus, vol.7, issue.3, pp.204-213, 2009.

R. Kralovics, A. Buser, S. Teo, J. Coers, A. Tichelli et al., Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders, Blood, vol.102, issue.5, pp.1869-71, 2003.
DOI : 10.1182/blood-2003-03-0744

S. Mustjoki, I. Borze, T. Lasho, R. Alitalo, A. Pardanani et al., JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV), Leukemia Research, vol.33, issue.1, pp.54-63, 2009.
DOI : 10.1016/j.leukres.2008.07.008

P. Goerttler, C. Steimle, E. Marz, P. Johansson, B. Andreasson et al., The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients, Blood, vol.106, issue.8, pp.2862-2866, 2005.
DOI : 10.1182/blood-2005-04-1515

B. Bellosillo, C. Besses, L. Florensa, F. Sole, and S. Serrano, JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders, Leukemia, vol.9, issue.4, pp.736-743, 2006.
DOI : 10.1038/sj.leu.2404123

D. Steensma, JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility, The Journal of Molecular Diagnostics, vol.8, issue.4, pp.397-411, 2006.
DOI : 10.2353/jmoldx.2006.060007

B. Cassinat, C. Laguillier, C. Gardin, V. De-beco, S. Burcheri et al., Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?, Leukemia, vol.22, issue.2, 2008.
DOI : 10.1055/s-2006-939433

P. Beer, P. Campbell, and A. Green, Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase, Haematologica, vol.95, issue.11, pp.1960-1963, 2010.
DOI : 10.3324/haematol.2010.026708

C. Harrison, D. Bareford, N. Butt, P. Campbell, E. Conneally et al., Guideline for investigation and management of adults and children presenting with a thrombocytosis, British Journal of Haematology, vol.100, issue.Suppl 1, pp.352-75, 2010.
DOI : 10.1111/j.1365-2141.2010.08122.x

G. Pernod, C. Biron-andreani, P. Morange, F. Boehlen, J. Constans et al., When to test for thrombophilia?]. Rev Prat, pp.1044-1050, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00683367

A. Remacha, C. Estivill, M. Sarda, M. J. Souto, J. Canals et al., The V617F mutation of JAK2 is very uncommon in patients with thrombosis, Haematologica, vol.92, issue.2, pp.285-291, 2007.
DOI : 10.3324/haematol.10358

F. Rouanet, I. Sibon, C. Goizet, P. Renou, and W. Meissner, Etiological assessment of cerebral infarct in the young. Proposals from the working group of the French Neuro-vascular Society, Rev Neurol, vol.165, issue.4, pp.283-291, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00626970

F. Cervantes, G. Barosi, J. Hernandez-boluda, M. Marchetti, and E. Montserrat, Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival, European Journal of Haematology, vol.93, issue.5, pp.324-331, 2001.
DOI : 10.1056/NEJM200004273421706